In this video, Dr. Brian G.M. Durie explains that even when a patient has MGUS, which is typically a benign stage in myeloma, problems can emerge.

BOTTOM LINE:
MGUS patients may benefit from treatment if the monoclonal protein has caused damage.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org


Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Previous Post
After relapse on CyBorD, what options are recommended?
Next Post
Which type of chromosome damage causes myeloma?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.